Novartis AG’s (NVS) Neutral Rating Reiterated at J P Morgan Chase & Co

J P Morgan Chase & Co restated their neutral rating on shares of Novartis AG (NYSE:NVS) in a research report sent to investors on Tuesday.

Several other equities research analysts have also recently commented on the company. Zacks Investment Research raised Novartis AG from a sell rating to a hold rating in a research note on Thursday, October 26th. Barclays PLC cut Novartis AG from an equal weight rating to an underweight rating in a research note on Wednesday, October 25th. Leerink Swann boosted their price target on Novartis AG from $89.00 to $91.00 and gave the company a market perform rating in a research note on Monday, October 23rd. BidaskClub raised Novartis AG from a sell rating to a hold rating in a research note on Saturday, August 19th. Finally, Cowen and Company set a $90.00 price target on Novartis AG and gave the company a hold rating in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company. Novartis AG presently has an average rating of Hold and a consensus target price of $85.28.

Novartis AG (NVS) opened at $83.70 on Tuesday. The company has a market capitalization of $195.82 billion, a P/E ratio of 17.43, a P/E/G ratio of 2.64 and a beta of 0.72. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32.

Novartis AG (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.04. The business had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS. equities analysts expect that Novartis AG will post 4.75 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2017/11/04/novartis-ags-nvs-neutral-rating-reiterated-at-j-p-morgan-chase-co.html.

Institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers bought a new stake in Novartis AG during the second quarter worth approximately $241,000. Bartlett & Co. LLC boosted its position in shares of Novartis AG by 1.6% in the third quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock valued at $40,614,000 after acquiring an additional 7,249 shares during the period. Westwood Holdings Group Inc. boosted its position in shares of Novartis AG by 5.6% in the first quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock valued at $401,000 after acquiring an additional 285 shares during the period. GFS Advisors LLC boosted its position in shares of Novartis AG by 6.5% in the second quarter. GFS Advisors LLC now owns 21,314 shares of the company’s stock valued at $1,779,000 after acquiring an additional 1,300 shares during the period. Finally, Schafer Cullen Capital Management Inc. boosted its position in shares of Novartis AG by 9.2% in the second quarter. Schafer Cullen Capital Management Inc. now owns 2,780,606 shares of the company’s stock valued at $232,097,000 after acquiring an additional 233,292 shares during the period. 10.94% of the stock is owned by hedge funds and other institutional investors.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit